Barmenia未来策略

2023年5月19日,

LUMO实验室和Barmenia在下一轮投资策略导致种子在德国创业Fimo健康新闻发布6月8日,2022埃因霍温,荷兰- LUMO实验室的计划投资工具LUMO基金Cooperatieve U.A.宣布七位数的投资在德国科隆数字医疗科技创业,利用数据来帮助患者应对慢性疾病的症状。Fimo健康是关闭其第一轮融资LUMO实验室和Barmenia未来战略,德国保险公司的风险手臂Barmenia,共同引领资本筹集。北威州。投资银行和Rockstart也。2020年初,本尼迪克特猪,亚历山大Krawinkel和杜米尼克Stiegeler Fimo成立健康作为慢性病症状管理平台集中在疲劳。价值主张Fimo健康的数据驱动的建议帮助病人更好地理解外部影响因素,利用相关知识的研究和临床实践主动消除疲劳等症状。“在各种讨论与影响,它已成为清楚我们多方面的疲劳,一般症状与慢性疾病管理是多么困难,”首席执行官Krawinkel说。“与我们的应用程序,我们想帮助那些受影响的正是解决这些问题,提高生活质量,但也使用数据与医生合作;例如,使监测和改善治疗。“两年来,Fimo健康长期发展计划Covid,多发性硬化症和肌痛性脑脊髓炎/慢性疲劳综合症(我/ CFS)在其CE-certified应用,是第一个注册医疗器械治疗Covid长。 Additional app versions incorporate content dealing with further symptoms or special features tailored to the specifics of the disease. “The app itself uses the smartphone, and different wearables can be connected to collect various vital and environmental parameters that can influence fatigue and other symptoms,” said Krawinkel. “In addition, the app collects further data via questionnaires and tests. With the help of our analysis of this data, patients can better understand their influencing factors and symptoms and proactively counteract them with the help of the program and tips and tricks.” The program covers various topics related to mindfulness, nutrition, exercise, energy and stress management and interaction with family and friends. More programs will follow during the year, e.g., in the oncology setting. Fimo Health’s technology not only empowers patients to use preventive measures, but it also aids insurance companies in reducing costs. Fimo Health already partners with several German public and private health insurers. “Fimo Health is the perfect example of how seemingly simple tools integrated in everyday devices can help relieve the impact of (semi-) chronic illness on patients and our healthcare system,” said Andy Lürling, LUMO Labs founding partner. “The Fimo Health ‘always on – always there’ mobile app allows patients to better understand the ‘why’ behind symptoms and flare-ups and provides actionable suggestions to prevent or minimize their impact.” “One of the distinctive qualities of Fimo Health’s founding team is their attention to the bigger picture,” said LUMO Labs Founding Partner Sven Bakkes. “They understand the value of their proposition lies not only in the quality of the tech, but just as much in having the right partnerships with multiple relevant stakeholders. “As such, we are delighted to co-invest alongside Barmenia Next Strategies, the Wuppertal-based venture arm of German insurance company Barmenia.” Fimo Health will use this investment to further expand its platform for fatigue and symptom management for chronic diseases. The team will use the next few months to become market leader in Germany, then expand abroad within two years. This is where LUMO Labs can provide great support to the Fimo team. Suggested Reading